Vinblastine
Vinblastine (vinblastine) is a small molecule pharmaceutical. Vinblastine was first approved as Velban on 1982-01-01. It is used to treat breast neoplasms, choriocarcinoma, head and neck neoplasms, histiocytosis, and hodgkin disease amongst others in the USA. The pharmaceutical is active against tubulin beta chain.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vinblastine sulfate | ANDA | 2019-12-31 |
Indications
FDA
EMA
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9360 | Injection, vinblastine sulfate, 1 mg |
Clinical
Clinical Trials
220 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 9 | 58 | 28 | 1 | 9 | 99 |
| Hodgkin disease | D006689 | — | C81 | 6 | 57 | 22 | 1 | 5 | 86 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | 6 | 1 | 1 | 10 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 21 | 7 | — | 2 | 29 |
| Transitional cell carcinoma | D002295 | — | — | 2 | 13 | 5 | — | 1 | 19 |
| Carcinoma | D002277 | — | C80.0 | 1 | 11 | 3 | — | 1 | 15 |
| Glioma | D005910 | EFO_0000520 | — | 3 | 6 | 2 | — | — | 11 |
| Melanoma | D008545 | — | — | 4 | 7 | 3 | — | — | 11 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 3 | 3 | 6 | — | — | 11 |
| Neoplasms | D009369 | — | C80 | 4 | 2 | 3 | — | — | 8 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 2 | 4 | 2 | — | — | 7 |
| Recurrence | D012008 | — | — | 1 | 3 | 1 | — | — | 5 |
| Urethral neoplasms | D014523 | EFO_0003846 | — | — | 2 | 4 | — | — | 5 |
Show 22 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Invasive hydatidiform mole | D002820 | — | D39.2 | 1 | 4 | — | — | — | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 4 | — | — | — | 5 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 4 | — | — | — | 4 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 3 | — | — | — | 3 |
| Central nervous system neoplasms | D016543 | — | — | 2 | 1 | — | — | — | 3 |
| Nervous system neoplasms | D009423 | — | — | 2 | 1 | — | — | — | 3 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 3 | — | — | — | 3 |
| Aggressive fibromatosis | D018222 | — | D48.11 | — | 2 | — | — | 1 | 3 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | — | 2 | — | — | — | 2 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | — | 2 | — | — | — | 2 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ataxia | D001259 | — | R27.0 | — | — | — | — | 1 | 1 |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
| Telangiectasis | D013684 | — | — | — | — | — | — | 1 | 1 |
| Cerebellar ataxia | D002524 | HP_0001251 | — | — | — | — | — | 1 | 1 |
| Infertility | D007246 | HP_0000789 | — | — | — | — | — | 1 | 1 |
| Constipation | D003248 | HP_0002019 | K59.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vinblastine |
| INN | vinblastine |
| Description | Vincaleukoblastine is a vinca alkaloid, an indole alkaloid fundamental parent, a methyl ester, an acetate ester, a tertiary alcohol, a tertiary amino compound, an organic heterotetracyclic compound and an organic heteropentacyclic compound. It has a role as a microtubule-destabilising agent, an antineoplastic agent, a plant metabolite and an immunosuppressive agent. |
| Classification | Small molecule |
| Drug class | antihistaminics (histamine-H1 receptor antagonists); vinca alkaloids |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1 |
Identifiers
| PDB | — |
| CAS-ID | 865-21-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL159 |
| ChEBI ID | — |
| PubChem CID | 241903 |
| DrugBank | DB00570 |
| UNII ID | 5V9KLZ54CY (ChemIDplus, GSRS) |
Target
Agency Approved
TUBB
TUBB
Organism
Homo sapiens
Gene name
TUBB
Gene synonyms
TUBB5
NCBI Gene ID
Protein name
tubulin beta chain
Protein synonyms
beta Ib tubulin, epididymis secretory sperm binding protein, tubulin beta-1 chain, Tubulin beta-5 chain, tubulin, beta polypeptide
Uniprot ID
Mouse ortholog
Tubb5 (22154)
tubulin beta-5 chain (Q3UF52)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 24,633 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,023 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use